For the last seven years, the LSX World Congress has bought together biotech, medtech and healthtech executives to connect with the capital, intelligence, innovation, and partners they need to grow their businesses. Back in-person for 2022, the 8th Congress takes place 10-11 May at 133 Houndsditch in London.   The event gathers the founders and CEOs of innovative […]

PerkinElmer has expanded its in vivo imaging portfolio with the launch of the Vega imaging system, an ultrasound platform that combines hands-free, automated technology with high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more.   The Vega system   The system eliminates challenges associated with conventional hand-held […]

Neuro-Bio, a biotechnology company developing a first-in-class treatment for neurodegenerative disease, has found its new drug candidate effectively treats the signs of neurodegeneration in a mouse model of Alzheimer’s disease. Publishing their work in Alzheimer’s & Dementia: Translational Research & Clinical Interventions (TRCI), Neuro-Bio researchers, in collaboration with the drug discovery company Evotec SE, UCLA, […]

Lonza has expanded its human stem cell offerings to provide human cord blood CD34+ haematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, meeting a rapidly expanding market need.  CB-CD34+ HSCs are the preferred cell choice for creating humanised mouse models, which are critical for preclinical safety testing of a range of immunotherapies. The new […]

C2i Genomics, a cancer intelligence company, has launched its C2inform minimal residual disease (MRD) test across Europe after obtaining CE-IVD marking in the EU, UK and Switzerland.   The company also announced the completion of several clinical trials across the globe, including cancer centers in Europe, US and Singapore.   The new clinical data will be presented […]

PerkinElmer has announced two ready-to-use HTRF and AlphaLISA no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing.   Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines and other biologics, must be free of residual host cell protein (HCP) impurities to prevent immunogenicity or reduced potency, stability or […]

When he was 17 years old, Joe Landolina created a revolutionary gel. Now, he is 29 years old and co-founder and CEO of Cresilon, his homegrown Brooklyn-based biotech company that recently submitted the gel for FDA 510(k) clearance for human use and raised $38.5 million in Series A3 financing last year. DDW’s Megan Thomas caught […]

Beckley Psytech, a company addressing neurological and psychiatric disorders through the application of psychedelic medicines, announced that the first healthy volunteers have been dosed in a Phase I clinical trial exploring the safety and pharmacokinetics of BPL-003, Beckley Psytech’s second formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT).  The study  The Phase I study is designed as a […]

News round-up by DDW’s Megan Thomas for 4-8 April   When considering trends in the drug discovery industry, the use of technology to advance treatments and therapeutics is consistently observed. DDW rounds up five of this week’s top news stories which reveal this theme of technology, AI and biotechnology.   1. Jumpcode Genomics launches tech to improve […]

At the end of last month, DDW’s Megan Thomas attended ELRIG’s Research & Innovation 2022: Innovations for Tomorrow’s Drug Discovery, at The King’s Centre in Oxford, UK. The four sessions addressed aspects of innovation across drug discovery and placed an emphasis on both the digital age and novel modalities: Omics technology innovations; The future of […]